恒瑞医药(01276.HK):HR-4375 注射液用于治疗胰腺癌适应症获得美国 FDA授予的孤儿药资格认定

智通财经
Jul 27
【恒瑞医药(01276.HK):HR-4375 注射液用于治疗胰腺癌适应症获得美国 FDA授予的孤儿药资格认定】智通财经APP讯,恒瑞医药(01276.HK)发布公告,近日,江苏恒瑞医药股份有限公司(以下简称“公司”)产品 SHR-4375 注射液用于治疗胰腺癌适应症获得美国食品药品监督管理局(以下简称“美国 FDA”)授予的孤儿药资格认定。孤儿药又称罕见病药,是指用于预防、治疗、诊断罕见病的药品。本次公司获得美国 FDA 孤儿药资格认定,将有机会在产品研发、注册及商业化等方面享受美国的政策支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10